A Phase Ib/II Randomised Open Label Study of BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib Compared to Pembrolizumab or Dabrafenib/Trametinib Alone, in Patients With Advanced Non-resectable (Stage IIIc) or Metastatic (Stage IV) Melanoma

Next Previous
Trial Profile

A Phase Ib/II Randomised Open Label Study of BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib Compared to Pembrolizumab or Dabrafenib/Trametinib Alone, in Patients With Advanced Non-resectable (Stage IIIc) or Metastatic (Stage IV) Melanoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 26 Mar 2018

At a glance

  • Drugs Bemcentinib (Primary) ; Dabrafenib; Pembrolizumab; Trametinib
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 22 Mar 2018 According to a BerGenBio media release, the company will present an overview and data summary of three phase II trials, including this trial, at the 3rd Annual Immuno-Oncology Summit Europe.
    • 29 Jan 2018 According to a BerGenBio media release, data from this study is presented at the ASCO-SITC Clinical Immuno-Oncology Symposium 2018.
    • 18 Oct 2017 According to a BerGenBio media release, the results and analysis from the dose-finding part of the study have been presented in a poster at the 9th World Congress of Melanoma.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top